Pie Healthcare Signs Utah MOU for US Market Entry

Pie Healthcare has signed a strategic business agreement with the University of Utah Medical Innovation Center to accelerate its entry into the North American market. The partnership focuses on securing U.S. Food and Drug Administration clearance for the company's proprietary medical artificial intelligence solutions, specifically the X-ANGIO and X-ADHD products. This collaboration provides Pie Healthcare with access to local regulatory infrastructure and clinical support, addressing the complex compliance requirements necessary for operating in the U.S. healthcare sector.

The agreement, reported by GN auto stocks/healthcare: medical device, outlines a pathway for the company to utilize the university’s resources to manage De Novo and 510(k) licensing procedures. Pie Healthcare aims to leverage this relationship to validate its technology through rigorous clinical processes, thereby reducing the operational risks associated with international market expansion. The move signals a shift from algorithm development to full-cycle commercialization, with a specific focus on overcoming regulatory barriers that typically delay the launch of diagnostic tools in the United States.

FDA clearance timeline for core AI products

The company targets FDA clearance for its vascular biomarker AI, X-ANGIO, between the end of 2027 and the first half of 2028. This timeline assumes that all regulatory procedures proceed without significant delay. X-ADHD, another key product in the Doctor IX-Series, will also undergo the licensing process through the same framework. By securing approval for these two flagship products, Pie Healthcare intends to establish a precedent for its broader portfolio, creating a template for future product launches in the global market.

New unit supports domestic startup commercialization

In addition to its own product pipeline, Pie Healthcare plans to launch a new business unit in 2027 to assist other Korean medical device startups. This division will offer full-cycle support for regulatory compliance and commercialization, targeting companies that possess strong technical capabilities but lack the resources to navigate clinical trials and licensing. The service scope includes certification for Quality Management Systems under ISO 13485 and Information Security under ISO 27001, as well as guidance for Ministry of Food and Drug Safety licensing for grade 2 and 3 devices.

The company intends to integrate these services into a unified system that connects development, clinical trials, and post-licensing distribution. By managing the entire lifecycle, Pie Healthcare aims to reduce the time and cost burden on partner startups. This strategy allows the company to diversify its revenue streams while building a network of domestic partners who can benefit from its established regulatory expertise and international connections.

AI agents reduce regulatory documentation costs

To enhance efficiency, Pie Healthcare is deploying specialized AI agents for regulatory and medical documentation. These tools are designed to automate the extensive data submission and clinical documentation required during the licensing process. By applying artificial intelligence to these administrative tasks, the company seeks to lower operational costs and shorten the timeline compared to traditional methods that rely heavily on external clinical research organizations. This technological integration supports the company’s goal of making the regulatory process more scalable for both internal products and external clients.